

Aditya Bagrodia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2021759/publications.pdf>

Version: 2024-02-01

205
papers

5,815
citations

94433

37
h-index

95266

68
g-index

211
all docs

211
docs citations

211
times ranked

6056
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Laboratory and Clinical Development of Single Keyhole Umbilical Nephrectomy. <i>Urology</i> , 2007, 70, 1039-1042. | 1.0 | 334 |
| 2 | Single-Incision, Umbilical Laparoscopic versus Conventional Laparoscopic Nephrectomy: A Comparison of Perioperative Outcomes and Short-Term Measures of Convalescence. <i>European Urology</i> , 2009, 55, 1198-1206. | 1.9 | 311 |
| 3 | Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. <i>European Urology</i> , 2017, 72, 952-959. | 1.9 | 263 |
| 4 | Radiation Exposure in the Acute and Short-Term Management of Urolithiasis at 2 Academic Centers. <i>Journal of Urology</i> , 2009, 181, 668-673. | 0.4 | 211 |
| 5 | Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015, 68, 970-977. | 1.9 | 202 |
| 6 | Guideline of guidelines: non-muscle-invasive bladder cancer. <i>BJU International</i> , 2017, 119, 371-380. | 2.5 | 195 |
| 7 | Natural History of Residual Fragments Following Percutaneous Nephrostolithotomy. <i>Journal of Urology</i> , 2009, 181, 1163-1168. | 0.4 | 178 |
| 8 | Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 967-976. | 7.0 | 164 |
| 9 | Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 4000-4007. | 1.6 | 147 |
| 10 | Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016, 48, 356-358. | 21.4 | 143 |
| 11 | Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy. <i>BJU International</i> , 2009, 104, 476-481. | 2.5 | 127 |
| 12 | Perioperative Outcomes in Patients Undergoing Conventional Laparoscopic Versus Laparoendoscopic Single-site Pyeloplasty. <i>Urology</i> , 2009, 74, 1029-1034. | 1.0 | 126 |
| 13 | Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. <i>European Urology</i> , 2019, 75, 231-239. | 1.9 | 104 |
| 14 | Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 27-32. | 1.6 | 78 |
| 15 | Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 604.e9-604.e17. | 1.6 | 77 |
| 16 | Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker. <i>Journal of Urology</i> , 2009, 182, 52-58. | 0.4 | 76 |
| 17 | Ergonomic Considerations of Radical Prostatectomy: Physician Perspective of Open, Laparoscopic, and Robot-Assisted Techniques. <i>Journal of Endourology</i> , 2009, 23, 627-633. | 2.1 | 73 |
| 18 | Complete Transvaginal NOTES Nephrectomy Using Magnetically Anchored Instrumentation. <i>Journal of Endourology</i> , 2009, 23, 367-371. | 2.1 | 69 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy. <i>European Urology</i> , 2013, 64, 465-471. | 1.9 | 68 |
| 20 | Deep Lateral Transurethral Incisions for Recurrent Bladder Neck Contracture: Promising 5-Year Experience Using a Standardized Approach. <i>Urology</i> , 2013, 82, 1430-1435. | 1.0 | 67 |
| 21 | Animal Protein and the Risk of Kidney Stones: A Comparative Metabolic Study of Animal Protein Sources. <i>Journal of Urology</i> , 2014, 192, 137-141. | 0.4 | 65 |
| 22 | Stereotactic Ablative Radiation Therapy (SABR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 367-375. | 0.8 | 65 |
| 23 | Impact of Body Mass Index on Cost and Clinical Outcomes After Percutaneous Nephrostolithotomy. <i>Urology</i> , 2008, 72, 756-760. | 1.0 | 64 |
| 24 | Residual Fragments After Percutaneous Nephrolithotomy: Cost Comparison of Immediate Second Look Flexible Nephroscopy Versus Expectant Management. <i>Journal of Urology</i> , 2010, 183, 188-193. | 0.4 | 60 |
| 25 | Robot-Assisted Bladder Neck Reconstruction, Bladder Neck Sling, and Appendicovesicostomy in Children: Description of Technique and Initial Results. <i>Journal of Endourology</i> , 2011, 25, 1299-1305. | 2.1 | 56 |
| 26 | Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2013, 81, 972-978. | 1.0 | 55 |
| 27 | Impact of hospital case volume on testicular cancer outcomes and practice patterns. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 14.e7-14.e15. | 1.6 | 55 |
| 28 | Discordance between Ureteroscopic Biopsy and Final Pathology for Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 199, 1440-1445. | 0.4 | 53 |
| 29 | PD-L1 detection using ⁸⁹ Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response. , 2019, 7, 144. | | 53 |
| 30 | OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230. | 2.1 | 51 |
| 31 | Genomic characterization of response to chemoradiation in urothelial bladder cancer. <i>Cancer</i> , 2016, 122, 3715-3723. | 4.1 | 50 |
| 32 | <scp>Ki67</scp> is an independent predictor of oncological outcomes in patients with localized clearâ€cell renal cell carcinoma. <i>BJU International</i> , 2014, 113, 668-673. | 2.5 | 49 |
| 33 | Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection. <i>European Urology</i> , 2020, 77, 290-292. | 1.9 | 48 |
| 34 | Favorable Patient Reported Outcomes After Penile Plication for Wide Array of Peyronie Disease Abnormalities. <i>Journal of Urology</i> , 2013, 189, 1019-1024. | 0.4 | 47 |
| 35 | Surgical Management of Renal Cell Carcinoma. <i>Seminars in Interventional Radiology</i> , 2014, 31, 027-032. | 0.8 | 46 |
| 36 | Predictors of Cost and Clinical Outcomes of Percutaneous Nephrostolithotomy. <i>Journal of Urology</i> , 2009, 182, 586-590. | 0.4 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 924-931. | 1.6 | 42 |
| 38 | Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. <i>European Urology Oncology</i> , 2019, 2, 397-404. | 5.4 | 42 |
| 39 | Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 981-988. | 1.6 | 39 |
| 40 | Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. <i>BJU International</i> , 2014, 113, 70-76. | 2.5 | 38 |
| 41 | Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract. <i>Journal of Urology</i> , 2015, 193, 1486-1493. | 0.4 | 38 |
| 42 | Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma. <i>Urology</i> , 2013, 81, 581-586. | 1.0 | 37 |
| 43 | Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. <i>Nature Communications</i> , 2020, 11, 1975. | 12.8 | 37 |
| 44 | Synchronous Bilateral Percutaneous Nephrostolithotomy: Analysis of Clinical Outcomes, Cost and Surgeon Reimbursement. <i>Journal of Urology</i> , 2009, 181, 149-153. | 0.4 | 36 |
| 45 | Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2016, 195, 1684-1689. | 0.4 | 36 |
| 46 | Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus—Safety Lead-in Results of a Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1135-1142. | 0.8 | 36 |
| 47 | Prospective Analysis of Ki-67 as an Independent Predictor of Oncologic Outcomes in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2014, 191, 28-34. | 0.4 | 35 |
| 48 | How Physician and Patient Perceptions Differ Regarding Medical Management of Stone Disease. <i>Journal of Urology</i> , 2009, 182, 998-1004. | 0.4 | 34 |
| 49 | MicroRNAs: Turning the Tide in Testicular Cancer. <i>European Urology</i> , 2019, 76, 541-542. | 1.9 | 34 |
| 50 | Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 54.e19-54.e26. | 1.6 | 31 |
| 51 | Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma. <i>Current Urology Reports</i> , 2016, 17, 12. | 2.2 | 30 |
| 52 | Comparison of Rates and Risk Factors for Development of Osteoporosis and Fractures After Radical or Partial Nephrectomy. <i>Urology</i> , 2011, 78, 614-619. | 1.0 | 29 |
| 53 | Prospective Comparison of Molecular Signatures in Urothelial Cancer of the Bladder and the Upper Urinary Tract—Is There Evidence for Discordant Biology?. <i>Journal of Urology</i> , 2014, 191, 926-931. | 0.4 | 29 |
| 54 | Prospects and progress of immunotherapy for bladder cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-15. | 3.1 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13. | 3.0 | 29 |
| 56 | Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. <i>Journal of Urology</i> , 2021, 205, 137-144. | 0.4 | 28 |
| 57 | A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. <i>European Urology Focus</i> , 2018, 4, 995-1001. | 3.1 | 26 |
| 58 | Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>European Urology Open Science</i> , 2021, 26, 83-87. | 0.4 | 26 |
| 59 | Preoperative Pulmonary Embolism Does Not Predict Poor Postoperative Outcomes in Patients with Renal Cell Carcinoma and Venous Thrombus. <i>Journal of Urology</i> , 2013, 190, 452-457. | 0.4 | 25 |
| 60 | Lymphovascular invasion in clear cell renal cell carcinoma—Association with disease-free and cancer-specific survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 30.e23-30.e28. | 1.6 | 24 |
| 61 | Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 268.e1-268.e7. | 1.6 | 24 |
| 62 | Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15-year experience and lessons learned. <i>BMC Urology</i> , 2016, 16, 43. | 1.4 | 24 |
| 63 | Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 57-62. | 1.6 | 24 |
| 64 | Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis. <i>Cancer</i> , 2021, 127, 850-864. | 4.1 | 24 |
| 65 | Laparoendoscopic Single-site Pyeloplasty: Outcomes of an International Multi-institutional Study of 140 Patients. <i>Urology</i> , 2013, 82, 366-372. | 1.0 | 23 |
| 66 | Prognostic Role of Cell Cycle and Proliferative Biomarkers in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2013, 190, 1662-1667. | 0.4 | 23 |
| 67 | Laparoendoscopic Single-site Nephrectomy Compared with Conventional Laparoscopic Nephrectomy: A 5-year, Single-surgeon Experience. <i>European Urology</i> , 2013, 64, 412-418. | 1.9 | 23 |
| 68 | New insights into germ cell tumor genomics. <i>Andrology</i> , 2019, 7, 507-515. | 3.5 | 23 |
| 69 | Initial Results for Combined Orchiectomy and Prosthesis Exchange for Unsalvageable Testicular Torsion in Adolescents: Description of Intravaginal Prosthesis Placement at Orchiectomy. <i>Journal of Urology</i> , 2012, 188, 1424-1428. | 0.4 | 22 |
| 70 | Comparison of rates and risk factors for development of anaemia and erythropoiesis-stimulating agent utilization after radical or partial nephrectomy. <i>BJU International</i> , 2012, 109, 1019-1025. | 2.5 | 22 |
| 71 | Dysregulation of β -Catenin is an Independent Predictor of Oncologic Outcomes in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 1671-1677. | 0.4 | 22 |
| 72 | Update on epidemiologic considerations and treatment trends in testicular cancer. <i>Current Opinion in Urology</i> , 2018, 28, 440-447. | 1.8 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Magnetic Resonance Imaging Radiomics Analyses for Prediction of High-Grade Histology and Necrosis in Clear Cell Renal Cell Carcinoma: Preliminary Experience. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 12-21.e1. | 1.9 | 22 |
| 74 | Evaluation of anatomic and morphologic nomogram to predict malignant and high-grade disease in a cohort of patients with small renal masses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 37.e17-37.e23. | 1.6 | 21 |
| 75 | Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 159.e7-159.e17. | 1.6 | 21 |
| 76 | Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 758-764. | 1.6 | 21 |
| 77 | Tissue-based biomarkers in prostate cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 249-260. | 0.7 | 20 |
| 78 | Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. <i>European Urology Focus</i> , 2019, 5, 365-368. | 3.1 | 20 |
| 79 | Impact of body mass index on clinical and cost outcomes after radical cystectomy. <i>BJU International</i> , 2009, 104, 326-330. | 2.5 | 19 |
| 80 | Surgeon Fatigue: Impact of Case Order on Perioperative Parameters and Patient Outcomes. <i>Journal of Urology</i> , 2012, 188, 1291-1296. | 0.4 | 19 |
| 81 | The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. <i>Urology</i> , 2018, 115, 119-124. | 1.0 | 19 |
| 82 | A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor Diagnosis. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 469-479. | 1.9 | 19 |
| 83 | Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2014, 84, 1134-1140. | 1.0 | 18 |
| 84 | Testicular germ cell tumor genomics. <i>Current Opinion in Urology</i> , 2017, 27, 41-47. | 1.8 | 18 |
| 85 | Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy. <i>European Urology Oncology</i> , 2019, 2, 691-698. | 5.4 | 18 |
| 86 | Robotic Nephroureterectomy <i>vs</i> Laparoscopic Nephroureterectomy: Increased Utilization, Rates of Lymphadenectomy, Decreased Morbidity Robotically. <i>Journal of Endourology</i> , 2021, 35, 312-318. | 2.1 | 18 |
| 87 | Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma. <i>Advances in Radiation Oncology</i> , 2021, 6, 100692. | 1.2 | 18 |
| 88 | Prospective Evaluation of Molecular Markers for the Staging and Prognosis of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2012, 62, e27-e29. | 1.9 | 17 |
| 89 | Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform. <i>Clinical Cancer Research</i> , 2021, 27, 4794-4806. | 7.0 | 17 |
| 90 | Are Urologists Fairly Reimbursed for Complex Procedures: Failure of 22 Modifier?. <i>Urology</i> , 2008, 72, 494-497. | 1.0 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. <i>Urology</i> , 2018, 112, 103-111. | 1.0 | 15 |
| 92 | Perioperative outcomes and cost of robotic vs open simple prostatectomy in the modern robotic era: results from the National Inpatient Sample. <i>BJU International</i> , 2021, 128, 168-177. | 2.5 | 15 |
| 93 | Does Obesity Impact the Costs of Partial and Radical Nephrectomy?. <i>Journal of Urology</i> , 2008, 179, 1714-1718. | 0.4 | 14 |
| 94 | Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1221-e1235. | 1.9 | 14 |
| 95 | Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. <i>European Urology Oncology</i> , 2018, 1, 242-251. | 5.4 | 14 |
| 96 | Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors. <i>Cancer</i> , 2019, 125, 3947-3952. | 4.1 | 14 |
| 97 | Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. <i>BJU International</i> , 2020, 128, 57-64. | 2.5 | 14 |
| 98 | Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. <i>Cancer</i> , 2020, 126, 4362-4370. | 4.1 | 14 |
| 99 | Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues. <i>Indian Journal of Urology</i> , 2009, 25, 169. | 0.6 | 14 |
| 100 | Does radical nephrectomy increase the risk of erectile dysfunction compared with partial nephrectomy? A cohort analysis. <i>BJU International</i> , 2013, 111, E98-102. | 2.5 | 12 |
| 101 | Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1487-1502. | 2.0 | 12 |
| 102 | Natural history of a second biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study. <i>BJU International</i> , 2018, 121, 365-372. | 2.5 | 12 |
| 103 | Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis. <i>BJU International</i> , 2019, 124, 792-800. | 2.5 | 12 |
| 104 | Gleason Grade Group Concordance between Preoperative Targeted Biopsy and Radical Prostatectomy Histopathologic Analysis: A Comparison Between In-Bore MRI-guided and MRI-Transrectal US Fusion Prostate Biopsies. <i>Radiology Imaging Cancer</i> , 2021, 3, e200123. | 1.6 | 12 |
| 105 | Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. <i>World Journal of Urology</i> , 2022, 40, 1505-1512. | 2.2 | 12 |
| 106 | Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. <i>BJU International</i> , 2021, 127, 108-113. | 2.5 | 11 |
| 107 | Risk prediction in the management of small renal masses. <i>Current Opinion in Urology</i> , 2012, 22, 347-352. | 1.8 | 10 |
| 108 | Renal Function After Laparoendoscopic Single Site Pyeloplasty. <i>Journal of Urology</i> , 2013, 190, 565-569. | 0.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Genetics of testicular germ cell tumors. <i>Current Opinion in Urology</i> , 2019, 29, 344-349. | 1.8 | 10 |
| 110 | Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 933.e7-933.e12. | 1.6 | 10 |
| 111 | Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 737.e11-737.e16. | 1.6 | 10 |
| 112 | Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 790.e1-790.e7. | 1.6 | 10 |
| 113 | Circulating MicroRNAs for Detection of Germ Cell Tumours: A Narrative Review. <i>European Urology Focus</i> , 2022, 8, 660-662. | 3.1 | 10 |
| 114 | Comparison of Tissue Oxygenation Profiles Using 3 Different Methods of Vascular Control During Porcine Partial Nephrectomy. <i>Urology</i> , 2009, 74, 926-931. | 1.0 | 9 |
| 115 | Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427. | 2.2 | 9 |
| 116 | Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. <i>European Urology Oncology</i> , 2020, 3, 198-206. | 5.4 | 9 |
| 117 | Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. <i>World Journal of Urology</i> , 2021, 39, 1977-1984. | 2.2 | 9 |
| 118 | Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , 2020, 4, 1307-1320. | 3.0 | 9 |
| 119 | Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management. <i>American Journal of Roentgenology</i> , 2020, 215, 267-276. | 2.2 | 9 |
| 120 | Robotic-Assisted Pyeloplasty: Recent Developments in Efficacy, Outcomes, and New Techniques. <i>Current Urology Reports</i> , 2013, 14, 37-40. | 2.2 | 8 |
| 121 | Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e21-18.e26. | 1.6 | 8 |
| 122 | Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. <i>Bladder Cancer</i> , 2016, 2, 91-99. | 0.4 | 8 |
| 123 | Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence. <i>Journal of Urology</i> , 2017, 198, 546-551. | 0.4 | 8 |
| 124 | Metastatic "Burned Out" Seminoma Causing Neurological Paraneoplastic Syndrome "Not Quite Burned Out". <i>Frontiers in Neurology</i> , 2018, 9, 20. | 2.4 | 8 |
| 125 | Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 736.e11-736.e18. | 1.6 | 8 |
| 126 | Impact of renal surgery for cortical neoplasms on lipid metabolism. <i>BJU International</i> , 2014, 114, 837-843. | 2.5 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. <i>World Journal of Urology</i> , 2016, 34, 105-112. | 2.2 | 7 |
| 128 | Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e113-e120. | 1.9 | 7 |
| 129 | Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence After Nephrectomy for Renal Cell Carcinoma. <i>Urology</i> , 2020, 145, 159-165. | 1.0 | 7 |
| 130 | Dynamic differences between DNA damage repair responses in primary tumors and cell lines. <i>Translational Oncology</i> , 2021, 14, 100898. | 3.7 | 6 |
| 131 | The Road Ahead for Circulating microRNAs in Diagnosis and Management of Testicular Germ Cell Tumors. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 269-271. | 3.8 | 6 |
| 132 | Management of Stage II Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2019, 46, 363-376. | 1.8 | 5 |
| 133 | Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 311-311. | 1.6 | 5 |
| 134 | Safety and feasibility of nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 619-619. | 1.6 | 5 |
| 135 | Staged Male Urethroplasty Transferring Megalourethra Tissue as Free Graft Dorsal Inlay to Proximal Urethral Atresia in VACTERL Association. <i>Urology</i> , 2011, 78, 1417-1419. | 1.0 | 4 |
| 136 | Re: Radiotherapy With or Without Chemotherapy in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2013, 63, 580-581. | 1.9 | 4 |
| 137 | The use of preoperative targeted molecular therapy to allow nephron sparing for T1b tumors. <i>Current Opinion in Urology</i> , 2013, 23, 411-417. | 1.8 | 4 |
| 138 | Statin utilization improves oncologic and survival outcomes in patients with dyslipidemia and surgically treated renal cell carcinoma. <i>Minerva Urology and Nephrology</i> , 2017, 69, 501-508. | 2.5 | 4 |
| 139 | Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 343.e1-343.e8. | 1.6 | 4 |
| 140 | Incidental Detection of Metastatic Penile Squamous-Cell Carcinoma With Antiâ€“1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid (18F-Fluciclovine) PET/CT in a Patient With Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e184-e186. | 1.9 | 4 |
| 141 | Actionable targets in patients with cisplatin-resistant advanced germ cell tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 473-473. | 1.6 | 4 |
| 142 | Predictive capacity of miRNA-375 in identifying teratoma in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).. <i>Journal of Clinical Oncology</i> , 2020, 38, 416-416. | 1.6 | 4 |
| 143 | Safety and Feasibility of Telehealth Only Preoperative Evaluation Before Minimally Invasive Robotic Urologic Surgery. <i>Journal of Endourology</i> , 2022, 36, 1070-1076. | 2.1 | 4 |
| 144 | Variation in the incidence of and risk factors for the development of nephrolithiasis after radical or partial nephrectomy. <i>BJU International</i> , 2010, 106, 1200-1204. | 2.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Clinical utility of the AJCC 8th edition pT1 subclassification and impact on practice patterns in stage I seminoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 136.e19-136.e25. | 1.6 | 3 |
| 146 | Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4510-4510. | 1.6 | 3 |
| 147 | Defining the DNA damage repair (DDR) genomic landscape of urothelial carcinoma of the bladder (UCB).. <i>Journal of Clinical Oncology</i> , 2018, 36, 502-502. | 1.6 | 3 |
| 148 | Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 724682. | 2.8 | 3 |
| 149 | Predictive factors of diagnostic delay and effect on treatment patterns in testicular germ cell tumor patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 201.e1-201.e7. | 1.6 | 3 |
| 150 | Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018, 36, 645-653. | 2.2 | 2 |
| 151 | Re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262â€“70. <i>European Urology</i> , 2018, 73, e98-e99. | 1.9 | 2 |
| 152 | Germ Cell Tumors: Updates on Epidemiology, Biology, and Treatment Considerations. <i>Advances in Urology</i> , 2018, 2018, 1-2. | 1.3 | 2 |
| 153 | Stereotactic Ablative Radiotherapy (SAbR) in the Setting of Metastatic Nonseminomatous Germ Cell Tumor of Testis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e768-e771. | 1.9 | 2 |
| 154 | Identification of testicular cancer driver genes by a crossâ€“species comparative oncology approach. <i>Andrology</i> , 2019, 7, 545-554. | 3.5 | 2 |
| 155 | The challenge of matching assays to biology in DNA damage response biomarkers for response to radiotherapy in bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, S514-S516. | 1.4 | 2 |
| 156 | Real-world application of pre-orchietomy miR-371a-3p test in testicular germ cell tumor (GCT) management.. <i>Journal of Clinical Oncology</i> , 2021, 39, 387-387. | 1.6 | 2 |
| 157 | Pre-orchietomy serum tumor markers as a predictor of recurrence in stage I germ cell tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 389-389. | 1.6 | 2 |
| 158 | Clinical utility of the AJCC eighth edition pT1 subclassification and impact on practice patterns in stage I seminoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 377-377. | 1.6 | 2 |
| 159 | Re: Lucia Nappi, Marisa Thi, Nabil Adra, et al. Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. <i>Eur Urol</i> 2021;79:16â€“9. <i>European Urology</i> , 2021, 79, e96-e97. | 1.9 | 2 |
| 160 | Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 788.e15-788.e21. | 1.6 | 2 |
| 161 | Validation of testicular germ cell tumor staging in nationwide cancer registries. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 838.e1-838.e6. | 1.6 | 2 |
| 162 | Holmium laser endourethrotomy and litholapaxy of an occult prostatic utricle calculus. <i>Canadian Journal of Urology</i> , 2012, 19, 6477-9. | 0.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Clinicopathologic predictors of outcomes in children with stage I testicular germ cell tumors: A pooled post hoc analysis of trials from the Children's Oncology Group. <i>Journal of Pediatric Urology</i> , 2022, 18, 505-511. | 1.1 | 2 |
| 164 | MP77-09 FEASIBILITY OF OBTAINING BIOMARKER PROFILES FROM ENDOSCOPIC BIOPSY SPECIMENS IN UPPER TRACT UROTHELIAL CARCINOMA: PRELIMINARY RESULTS. <i>Journal of Urology</i> , 2014, 191, . | 0.4 | 1 |
| 165 | Is Malignant Germ-Cell Tumor Associated With Cowden Syndrome?. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e429-e432. | 1.9 | 1 |
| 166 | Safety, Efficacy, and Impact on Quality of Life of Palliative Robotic Cystectomy for Advanced Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e129-e134. | 1.9 | 1 |
| 167 | Disparities in Pre-Orchiectomy Sperm Cryopreservation Among Testicular Cancer Patients at a Public Safety Net Hospital and a Private Tertiary Care Center. <i>Urology</i> , 2021, , . | 1.0 | 1 |
| 168 | Utilization and survival implications of a delayed approach to targeted therapy for metastatic renal cell carcinoma: A nationwide cancer registry study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 586-586. | 1.6 | 1 |
| 169 | The early impact of medicaid expansion on urologic malignancies in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 103.e1-103.e1. | 1.6 | 1 |
| 170 | Performance characteristics of 18F-Fluciclovine positron emission tomography/computed tomography prior to retroperitoneal lymph node dissection.. <i>Journal of Clinical Oncology</i> , 2020, 38, 390-390. | 1.6 | 1 |
| 171 | Serum microRNA-371a-3p levels to predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.. <i>Journal of Clinical Oncology</i> , 2020, 38, 417-417. | 1.6 | 1 |
| 172 | The Past and Future of Biomarkers in Testicular Germ Cell Tumors. <i>Société Internationale D'urologie Journal</i> , 2020, 1, 77-84. | 0.4 | 1 |
| 173 | Performance characteristics of 18F-fluciclovine positron emission tomography/computed tomography prior to retroperitoneal lymph node dissection. <i>Canadian Urological Association Journal</i> , 2021, 16, E167-E172. | 0.6 | 1 |
| 174 | Are we likely to see more of LESS in urological surgery?. <i>Nature Reviews Urology</i> , 2012, 9, 185-186. | 3.8 | 0 |
| 175 | Re: Multi-institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy. <i>European Urology</i> , 2017, 72, 857-858. | 1.9 | 0 |
| 176 | Reply. <i>Urology</i> , 2018, 112, 111. | 1.0 | 0 |
| 177 | Editorial comment. <i>Current Opinion in Urology</i> , 2018, 28, 433-434. | 1.8 | 0 |
| 178 | Considerations When Treating Patients with Good-risk Germ Cell Tumors. <i>European Urology Focus</i> , 2020, 6, 1195-1198. | 3.1 | 0 |
| 179 | Validation of testicular germ cell tumor (GCT) staging in nationwide cancer registries.. <i>Journal of Clinical Oncology</i> , 2021, 39, 383-383. | 1.6 | 0 |
| 180 | Sarcopenia prior to and following chemotherapy to predict morbidity in patients undergoing post-chemotherapy retroperitoneal lymphadenectomy (PC-RPLND).. <i>Journal of Clinical Oncology</i> , 2021, 39, 381-381. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Reply to So, now what?: Reflections on socioeconomic factors, testicular cancer, and health care accessibility. <i>Cancer</i> , 2021, 127, 1347-1348. | 4.1 | 0 |
| 182 | Encouraging Outcomes Allow Patient-Guided Treatment Strategies for Stage I Pure Testicular Teratoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 3465-3467. | 1.5 | 0 |
| 183 | How can we mitigate treatment-associated morbidity in patients with germ cell tumors?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 805-807. | 2.4 | 0 |
| 184 | Progress and challenges in testicular cancer microRNAs. <i>Asian Journal of Urology</i> , 2021, 8, 341-342. | 1.2 | 0 |
| 185 | Assessment of intratumor heterogeneity using imaging texture features in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 663-663. | 1.6 | 0 |
| 186 | Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 651-651. | 1.6 | 0 |
| 187 | Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 599-599. | 1.6 | 0 |
| 188 | Pathologic response and surgical outcomes in patients undergoing nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16102-e16102. | 1.6 | 0 |
| 189 | Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16100-e16100. | 1.6 | 0 |
| 190 | Dynamic contrast-enhanced MRI to predict intratumoral molecular heterogeneity in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4580-4580. | 1.6 | 0 |
| 191 | Overcoming sociodemographic factors in the care of testicular cancer patients at a safety net hospital.. <i>Journal of Clinical Oncology</i> , 2020, 38, 398-398. | 1.6 | 0 |
| 192 | Genomic determinants of nested variant urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 538-538. | 1.6 | 0 |
| 193 | Effect of increasing Medicaid coverage in Medicaid expansion states on stage at presentation for urologic malignancies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 400-400. | 1.6 | 0 |
| 194 | Germ Cell Tumor Cell Culture Techniques. <i>Methods in Molecular Biology</i> , 2021, 2195, 65-76. | 0.9 | 0 |
| 195 | Clinicopathologic predictors of outcomes in children with stage I germ cell tumors: A pooled post hoc analysis of trials from the Childrenâ€™s Oncology Group.. <i>Journal of Clinical Oncology</i> , 2020, 38, 418-418. | 1.6 | 0 |
| 196 | First Do No Harm: A Cautious, Risk-adapted Approach to Testicular Cancer Patients. <i>Reviews in Urology</i> , 2020, 22, 85-89. | 0.9 | 0 |
| 197 | Re: Anthony Emmanuel, Abi Kanthabalan, Cameron Alexander, et al. Expedited Radical Orchiectomy for Testicular Cancer: Compromising Fertility Outcomes Without Oncological Benefit? <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2021.08.025 . <i>European Urology</i> , 2021, 81, e50-e50. | 1.9 | 0 |
| 198 | Survival of nonseminomatous germ cell tumors in pediatric patients and young adults â€” A stage group stratified analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , . | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Evaluation of a risk-adapted strategy in the primary surgical management of clinical stage IIA testicular cancer.. Journal of Clinical Oncology, 2022, 40, 414-414. | 1.6 | 0 |
| 200 | Molecular analysis of primary testicular germ cell tumor and matched metastatic teratomas.. Journal of Clinical Oncology, 2022, 40, 425-425. | 1.6 | 0 |
| 201 | Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer. Frontiers in Oncology, 2022, 12, 779182. | 2.8 | 0 |
| 202 | Evaluating the discriminatory capacity of miR-371A-3P in the context of pure seminomatous testicular cancer metastases.. Journal of Clinical Oncology, 2022, 40, 424-424. | 1.6 | 0 |
| 203 | Optimization of serum miR-371a-3p for the detection of chemotherapy-naïve minimal residual germ cell tumor.. Journal of Clinical Oncology, 2022, 40, 423-423. | 1.6 | 0 |
| 204 | Role of preoperative albumin in predicting risk of postoperative complications in patients undergoing post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).. Journal of Clinical Oncology, 2022, 40, 416-416. | 1.6 | 0 |
| 205 | Decreased Muscle Mass Prior to and Following Chemotherapy Predicts Morbidity in Testicular Cancer Patients Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection. Clinical Genitourinary Cancer, 2022, 20, e460-e464. | 1.9 | 0 |